Breast cancer, Secondary cancers
Open
Phase 3
This study is looking at a drug called inavolisib for breast cancer that has spread to another part of the body or into the surrounding tissue.
It is open to people with breast cancer that:
has receptors for the hormones oestrogen (ER positive) or progesterone (PR positive), or both
does not have receptors for HER2 (HER2 negative)
You pronounce inavolisib as in-avo-lis-ib.
Recruitment start: 1 April 2025
Recruitment end: 30 November 2027
Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.
Dr Tuthill
F.Hoffmann-La Roche Ltd (Roche)
Last reviewed: 14 Jan 2026
CRUK internal database number: 20126
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
